Nickel-Free and Circular: What the Siegel TAVI Valve's Early Data Mean for Practice and Portfolio
A novel balloon-expandable, nickel-free transcatheter valve posted low pacemaker rates and stable two-year hemodynamics at New York Valves 2026 — and a $1.5 billion industry bet suggests Wall Street is paying attention too.
A new entrant in the crowded transcatheter aortic valve implantation (TAVI) field is drawing attention for solving two problems at once.
The Siegel valve, developed by MiRus, is built from a proprietary molybdenum-rhenium alloy rather than the nickel-titanium nitinol used in most commercial platforms.
That single material change addresses an estimated 20% of Americans with nickel sensitivity who have historically been poor candidates for self-expanding nitinol valves.
Early feasibility and first-in-human data presented at New York Valves 2026 showed acute procedural success in all cases, a low new-pacemaker rate, and hemodynamics that held steady out to two years.
For practicing interventional and general cardiologists, the device is not yet commercially available, but its design logic and its emerging industry backing are worth understanding now.
A 78-year-old patient with severe, symptomatic aortic stenosis and a documented history of a contact dermatitis reaction to a nickel-containing orthopedic implant is referred for valve evaluation.
Computed tomography shows a heavily calcified, mildly bicuspid annulus with iliofemoral vessels too small for standard 14-Fr delivery systems.
The heart team is hesitant to proceed with a nitinol-frame self-expanding valve given the allergy history, and the patient is anxious about being "turned away" from a minimally invasive option.
This is the patient population in which investigational nickel-free, low-profile platforms such as the Siegel valve are being studied, and a structural heart referral for trial screening — rather than default surgical referral — may be appropriate where enrollment is open.
An Engineering Story Built Around Three Problems
Conventional self-expanding TAVI frames rely on nitinol for its shape-memory and superelastic properties, but nitinol contains nickel and titanium and can foreshorten during deployment.
The Siegel platform instead uses a molybdenum-rhenium "MoRe" superalloy with vertical stent rods designed to eliminate foreshortening entirely, which the developer says improves positioning precision and may lower conduction-system trauma.
The frame is coated with nitric oxide, a strategy intended to support endothelial healing and reduce the inflammatory response that can contribute to leaflet thrombosis.
Commissural alignment flags built into the frame let operators visualize and rotate the valve into the optimal commissural position before final deployment, rather than relying on post-hoc imaging correction.
The valve also arrives pre-mounted on its delivery balloon, removing a manual crimping step that exists with some other balloon-expandable systems.
Delivery occurs through an 8-Fr expandable sheath, roughly half the profile of many currently marketed systems, which may extend transfemoral eligibility to patients with smaller-caliber peripheral vessels, including more women.
| Feature | Siegel (MiRus, investigational) | Sapien 3 family (Edwards Lifesciences) | Evolut family (Medtronic) |
|---|---|---|---|
| Frame alloy | Molybdenum-rhenium (nickel-free) | Cobalt-chromium | Nitinol (nickel-titanium) |
| Deployment mechanism | Balloon-expandable | Balloon-expandable | Self-expanding |
| Delivery sheath | 8-Fr expandable | 14-Fr (eSheath) | 14-Fr (self-expanding system) |
| Foreshortening | Designed to eliminate | Standard for class | Greater, by design (supra-annular) |
| Leaflet ellipticity ratio, tricuspid | 1.02 (reported) | 1.09 (reported) | 1.20 (reported) |
| Sizes available in study | 23, 26, 29 mm | 20–29 mm range | 23–34 mm range |
| Regulatory status | Investigational (STAR trial enrolling) | FDA-approved, commercial | FDA-approved, commercial |
What the First-in-Human and Feasibility Data Showed
The pooled experience includes five patients treated in a first-in-human cohort in Chile and 30 patients enrolled in a nine-site United States early feasibility study, for a combined 35 patients.
Mean age in the feasibility cohort was 76 years, 57% were male, mean Society of Thoracic Surgeons score was 2.81%, and 80% were classified as low surgical risk.
All procedures used transfemoral access, positioning and commissural alignment were achieved in every case, and mean time from sheath insertion to valve deployment was 15 minutes.
One death unrelated to the valve occurred by six months (under 1%), and three patients required a new permanent pacemaker (8.5%).
No strokes, annular ruptures, need for a second valve, reinterventions, major vascular complications, significant bleeding, more-than-moderate aortic regurgitation, or acute kidney injury were reported through the available follow-up.
Three of the 35 patients had previously been declined for TAVI elsewhere specifically because of severe nickel allergy.
Aortic valve area improved in parallel, increasing from 0.8 to 2.0 cm² in the first-in-human cohort, from 0.8 to 2.5 cm² for the 26-mm EFS valve, and from 0.7 to 2.2 cm² for the 23-mm EFS valve.
The presenting investigator described the stability of these gradients and areas out to two years as the most clinically important early signal, particularly because smaller valve sizes are typically where prosthesis-patient mismatch becomes most apparent with existing platforms.
The Circularity-Durability Hypothesis
A recurring theme at the session was whether a valve with high radial force and minimal recoil might be more prone to annular injury in heavily calcified anatomy.
The presenting investigator argued that rupture risk relates more to oversizing strategy than to absolute radial force, and that because the Siegel frame does not require hyperinflation to compensate for recoil, the balloon can target a narrower 0–2% oversizing range.
On that basis, the feasibility study enrolled patients with aortic valve calcium scores up to 7,000 Agatston units, including bicuspid anatomy, contingent on heart-team and review-committee sign-off.
Investigators also pointed to valve "circularity" — how closely the deployed orifice approximates a true circle — as an underappreciated durability variable, since an elliptical orifice can produce regions of leaflet stress concentration.
Leaflet sourcing was also highlighted as a differentiator, with the developer reportedly applying selective screening of porcine pericardial tissue for thickness uniformity and collagen cross-linkage before use.
Whether these design choices translate into superior long-term durability remains unproven, and panel discussants were careful to note that the benchmark — the Sapien 3 platform's own long-term performance — is a high bar.
Where the Program Goes Next
The pivotal STAR trial is now enrolling roughly 1,000 to 1,025 patients with severe, symptomatic aortic stenosis across the risk spectrum, randomizing them to the Siegel valve or a commercially available balloon-expandable or self-expanding device.
The primary endpoint is a composite of mortality, stroke, and cardiovascular hospitalization at one year.
Current access is limited to enrolling STAR trial sites, and the device has no FDA approval or commercial pricing at this time.
Operators interested in offering the technology to nickel-allergic or small-vessel patients should look for STAR trial participation among regional structural heart programs rather than expecting near-term commercial access.
The Investing Angle: A $1.5 Billion Signal
In May 2026, Boston Scientific invested $1.5 billion in MiRus, acquiring a 34% equity stake along with an exclusive option to acquire the Siegel TAVR business outright for an additional $3 billion if the program hits clinical and regulatory milestones.
The move marks Boston Scientific's third attempt to break into the TAVI market after its earlier Acurate and Lotus Edge platforms were discontinued, and it gives the company a stake in a technology explicitly positioned as nickel-free and differentiated rather than a me-too valve.
For a physician-investor audience, the deal is a reminder that device-maker valuations can move on early-stage structural heart bets long before FDA approval or revenue materializes.
The broader TAVI market remains a duopoly in practice, with Edwards Lifesciences and Medtronic together accounting for the overwhelming majority of commercial implants, which is the incumbency Boston Scientific is trying to disrupt with this investment.
| Company | Ticker | Recent share price | Relevance to Siegel/TAVI |
|---|---|---|---|
| Boston Scientific Corporation | NYSE: BSX | ~$43–46 | $1.5B investment for 34% stake in MiRus; exclusive option to acquire Siegel TAVR business for $3B more |
| Edwards Lifesciences Corporation | NYSE: EW | ~$90–91 | Maker of the Sapien 3 family; dominant incumbent balloon-expandable platform |
| Medtronic plc | NYSE: MDT | ~$80–81 | Maker of the Evolut family; dominant incumbent self-expanding platform |
On reimbursement, it is worth noting that none of the commercial valves' device-level acquisition costs are publicly itemized, since CMS bundles transcatheter valve procedures into inpatient diagnosis-related group payments rather than reimbursing the valve as a separate line item.
Total one-year episode costs for balloon-expandable TAVR have been estimated in the $80,000 range in published cost-utility analyses, a figure that includes the device, procedure, hospitalization, and follow-up rather than device acquisition cost alone.
Should the Siegel valve reach approval, its eventual pricing will likely be set competitively against this established episode-cost backdrop rather than as a stand-alone premium product.
- The Siegel valve is an investigational, nickel-free, balloon-expandable TAVI platform showing low pacemaker rates, stable two-year hemodynamics, and a markedly more circular deployed frame than two leading commercial comparators in early data.
- It is not yet FDA-approved; access is currently limited to the enrolling STAR pivotal trial, and clinicians should not expect near-term commercial availability.
- The device may be particularly relevant for patients with documented nickel allergy or small peripheral vessels once broader access is available.
- Boston Scientific's $1.5 billion equity investment and acquisition option signal industry confidence but do not substitute for pivotal-trial efficacy and durability data, which will not mature for several years.
References
- Why Boston Scientific is betting $1.5B on this TAVR superalloy. Medical Design & Outsourcing, June 2026.
- MiRus treats first patients in STAR trial of Siegel 8-French heart valve. Medical Device Network, April 2026.
- What's Going to Be Hot at New York Valves 2026. TCTMD, June 2026.
- Target: Aortic Stenosis initiative. American Heart Association.
- Boston Scientific Corporation (BSX) stock overview. StockAnalysis.com.
- Edwards Lifesciences Corporation (EW) stock overview. StockAnalysis.com.
- Medtronic plc (MDT) stock overview. StockAnalysis.com.
- Transcatheter SAPIEN 3 Ultra valve. Edwards Lifesciences.
- SAPIEN 3 Valve Demonstrates Significant Cost Savings Over Surgery in Intermediate-Risk Patients. Diagnostic and Interventional Cardiology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.